aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Positive Data from a Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response of ATYR1923 in Pulmonary Sarcoidosis
13 sept. 2021 07h30 HE
|
aTyr Pharma, Inc.
Pangu’s basic and translational research in tRNA synthetase biology, conducted in collaboration with the Hong Kong University of Science and Technology, contributed to successful clinical...
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
13 sept. 2021 07h30 HE
|
aTyr Pharma, Inc.
Trial met primary endpoint, ATYR1923 was safe and well-tolerated. Efficacy observed in key endpoints including steroid reduction of 58% in the 5.0 mg/kg treatment group with 33% of patients in the...
aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update
10 août 2021 16h00 HE
|
aTyr Pharma, Inc.
Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021. Company to host conference call and webcast today, August 10th, at 5:00 p.m. EDT / 2:00 p.m....
aTyr Pharma Announces Expansion of Research Collaboration with The Ohio State University
10 août 2021 08h00 HE
|
aTyr Pharma, Inc.
Collaboration led by Dr. Elliott Crouser to explore underlying cellular mechanisms of pulmonary sarcoidosis and identify potential sarcoidosis biomarkers. SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE)...
aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress
09 août 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
03 août 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung
29 juil. 2021 16h05 HE
|
aTyr Pharma, Inc.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
08 juil. 2021 08h00 HE
|
aTyr Pharma, Inc.
Results from proof-of-concept study are expected in September 2021. SAN DIEGO, July 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery...
aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis
23 juin 2021 08h00 HE
|
aTyr Pharma, Inc.
Event will feature Dr. Daniel Culver, Director of the Interstitial Lung Disease Program at the Cleveland Clinic. Conference call and webcast scheduled for Tuesday June 29th at 5:00pm ET/2:00pm PT. ...
aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody
10 juin 2021 16h30 HE
|
aTyr Pharma, Inc.
Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2. aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways which are...